Tumor vaccines have been an attractive concept in the immunotherapy of cancer based on
the central role of tumor-associated antigens in allowing the immune system to recognize …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Therapeutic cancer vaccines have been a subject of research for several decades as
potential new weapons to tackle malignancies. Their goal is to induce a long-lasting and …

The promise of immune-based therapies to treat cancer has been realized over the last
several years with several breakthrough therapies, including T-cell checkpoint inhibitors and …

Recent developments in several areas are rekindling interest and empowering progress in
improving therapeutic cancer vaccines. These advances have been made in target …

Lack of tumor T-cell infiltration is a barrier to the efficacy of immune checkpoint inhibitors and
other immunotherapies in patients with cancer. Because of their ability to activate and …

Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

There are strong biologic and preclinical rationales for the development of therapeutic
cancer vaccines; however, the clinical translation of this treatment strategy has been …

Immunotherapy is emerging as a promising anti-cancer curative modality. However, in
contrast to recent advances obtained employing checkpoint blockade agents and T cell …

Therapeutic cancer vaccines have become increasingly qualified for use in personalized
cancer immunotherapy. A deeper understanding of tumor immunology and novel antigen …